A Korean study suggests that starting glucose-lowering medication soon after a type 2 diabetes diagnosis significantly improves long-term survival rates and reduces the risk of cardiovascular disease, highlighting the importance of prompt treatment.
A new Korean study suggests that starting diabetes medication soon after a type 2 diagnosis may improve long-term survival and lower the risk of cardiovascular disease.
Researchers from Sungkyunkwan University and Kangbuk Samsung Hospital analysed health-check data and National Health Insurance records for 23,452 Korean adults newly diagnosed with type 2 diabetes, defining diagnosis by glycated haemoglobin of at least 6.5% or fasting glucose of 126 mg/dL or higher. They divided patients by how quickly they began glucose-lowering treatment: within three months, within six months, within 12 months, or not within 12 months, then followed them for five years.
The findings, published in JAMA Network Open, showed a consistent pattern: the earlier treatment began, the lower the risk of major cardiovascular events tended to be. The most striking result was among patients who started medication within three months of diagnosis, who had a 69% lower risk of death within five years than those who went untreated for more than a year.
Lead researcher Jang Yoo-soo of Kangbuk Samsung Hospital said the study found that more than half of participants did not start drug treatment during the five-year follow-up period, underscoring how often treatment is deferred after diagnosis. The result fits with earlier research suggesting that rapid improvements in blood glucose after starting oral therapy are linked with fewer major cardiovascular events, while early intensive management of multiple risk factors can also cut later complications.
The new analysis adds weight to a broader evidence base indicating that timing matters in type 2 diabetes care. Earlier studies have found that lower HbA1c levels achieved soon after treatment begins are associated with better cardiovascular outcomes, and that metformin generally compares more favourably than sulphonylureas as an initial treatment option. Taken together, the research points to a simple message: for many patients, earlier action after diagnosis may translate into better long-term outcomes.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
